Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso
Traceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/7938130 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556366353399808 |
|---|---|
| author | Salam Sawadogo Koumpingnin Nebie Tieba Millogo Sonia Sontie Ashmed Nana Honorine Dahourou Dieudonné Yentema Yonli Jean-Baptiste Tapko Jean-Claude Faber Eléonore Kafando Véronique Deneys |
| author_facet | Salam Sawadogo Koumpingnin Nebie Tieba Millogo Sonia Sontie Ashmed Nana Honorine Dahourou Dieudonné Yentema Yonli Jean-Baptiste Tapko Jean-Claude Faber Eléonore Kafando Véronique Deneys |
| author_sort | Salam Sawadogo |
| collection | DOAJ |
| description | Traceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over the 6-year postpilot phase. A cross-sectional study including all blood units ordered between 2010 and 2015 has been conducted in public and private health care facilities supplied with blood products by the transfusion center of Bobo-Dioulasso. The complete traceability was possible for 83.5% of blood units delivered. Adverse reactions were reported in 107 cases representing 2.1/1,000 blood units per annum. Transfusions of wrong blood to wrong patient were reported in 13 cases. Our study shows that the haemovigilance system in Burkina Faso must be improved. Healthcare workers have to be sensitized on how traceability and haemovigilance could impact the quality of care provided to patients. |
| format | Article |
| id | doaj-art-d665984a86e3493e90d29366198a85ed |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-d665984a86e3493e90d29366198a85ed2025-02-03T05:45:40ZengWileyAdvances in Hematology1687-91041687-91122018-01-01201810.1155/2018/79381307938130Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina FasoSalam Sawadogo0Koumpingnin Nebie1Tieba Millogo2Sonia Sontie3Ashmed Nana4Honorine Dahourou5Dieudonné Yentema Yonli6Jean-Baptiste Tapko7Jean-Claude Faber8Eléonore Kafando9Véronique Deneys10University Ouaga I Professor Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina FasoUniversity Ouaga I Professor Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina FasoAfrican Institute of Public Health, 12 BP 199 Ouagadougou, Burkina FasoNational Blood Transfusion Centre, 01 BP 5372 Ouagadougou, Burkina FasoNational Blood Transfusion Centre, 01 BP 5372 Ouagadougou, Burkina FasoNational Blood Transfusion Centre, 01 BP 5372 Ouagadougou, Burkina FasoNational Blood Transfusion Centre, 01 BP 5372 Ouagadougou, Burkina FasoAfrican Society for Blood Transfusion, CameroonAssociation Luxembourgeoise des Hémophiles, 33 rue Albert Ier, 1117, LuxembourgUniversity Ouaga I Professor Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, Burkina FasoCHU UCL Namur asbl, 15 place L. Godin, 5000 Namur, BelgiumTraceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over the 6-year postpilot phase. A cross-sectional study including all blood units ordered between 2010 and 2015 has been conducted in public and private health care facilities supplied with blood products by the transfusion center of Bobo-Dioulasso. The complete traceability was possible for 83.5% of blood units delivered. Adverse reactions were reported in 107 cases representing 2.1/1,000 blood units per annum. Transfusions of wrong blood to wrong patient were reported in 13 cases. Our study shows that the haemovigilance system in Burkina Faso must be improved. Healthcare workers have to be sensitized on how traceability and haemovigilance could impact the quality of care provided to patients.http://dx.doi.org/10.1155/2018/7938130 |
| spellingShingle | Salam Sawadogo Koumpingnin Nebie Tieba Millogo Sonia Sontie Ashmed Nana Honorine Dahourou Dieudonné Yentema Yonli Jean-Baptiste Tapko Jean-Claude Faber Eléonore Kafando Véronique Deneys Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso Advances in Hematology |
| title | Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso |
| title_full | Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso |
| title_fullStr | Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso |
| title_full_unstemmed | Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso |
| title_short | Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso |
| title_sort | traceability of blood transfusions and reporting of adverse reactions in developing countries a six year postpilot phase experience in burkina faso |
| url | http://dx.doi.org/10.1155/2018/7938130 |
| work_keys_str_mv | AT salamsawadogo traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT koumpingninnebie traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT tiebamillogo traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT soniasontie traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT ashmednana traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT honorinedahourou traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT dieudonneyentemayonli traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT jeanbaptistetapko traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT jeanclaudefaber traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT eleonorekafando traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso AT veroniquedeneys traceabilityofbloodtransfusionsandreportingofadversereactionsindevelopingcountriesasixyearpostpilotphaseexperienceinburkinafaso |